company background image
IMR logo

AC Immune DB:IMR Stock Report

Last Price

€2.76

Market Cap

€246.5m

7D

-7.7%

1Y

31.8%

Updated

27 Mar, 2024

Data

Company Financials +

IMR Stock Overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.

IMR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AC Immune SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AC Immune
Historical stock prices
Current Share PriceUS$2.76
52 Week HighUS$4.65
52 Week LowUS$1.60
Beta1.02
1 Month Change-15.34%
3 Month Change-37.20%
1 Year Change31.81%
3 Year Change-56.84%
5 Year Change-35.81%
Change since IPO-80.29%

Recent News & Updates

Recent updates

Shareholder Returns

IMRDE BiotechsDE Market
7D-7.7%2.1%1.9%
1Y31.8%37.0%7.3%

Return vs Industry: IMR underperformed the German Biotechs industry which returned 37% over the past year.

Return vs Market: IMR exceeded the German Market which returned 7.3% over the past year.

Price Volatility

Is IMR's price volatile compared to industry and market?
IMR volatility
IMR Average Weekly Movement11.7%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: IMR's share price has been volatile over the past 3 months.

Volatility Over Time: IMR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2003147Andrea Pfeiferhttps://www.acimmune.com

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer’s disease (AD).

AC Immune SA Fundamentals Summary

How do AC Immune's earnings and revenue compare to its market cap?
IMR fundamental statistics
Market cap€246.47m
Earnings (TTM)-€55.37m
Revenue (TTM)€15.11m

16.3x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMR income statement (TTM)
RevenueCHF14.80m
Cost of RevenueCHF54.61m
Gross Profit-CHF39.80m
Other ExpensesCHF14.43m
Earnings-CHF54.23m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.58
Gross Margin-268.93%
Net Profit Margin-366.41%
Debt/Equity Ratio0%

How did IMR perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.